Table 1
| Disease Site |
Study | Study Name | Open Date | Number of Active Institutions |
Number of Current IRBs |
|---|---|---|---|---|---|
| BREAST | S1207 | Brst,Adj,Endocrine+/-Everolimus | 03-SEP-13 | 442 | 207 |
| S1416 | Brst, TNBC/BRCA, Cis+/- ABT-888 | 07-JUL-16 | 275 | 131 | |
| S1418 | Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 15-NOV-16 | 476 | 211 | |
| S1706 | Breast, Inflammatory, RT +/- Olaparib | 12-SEP-18 | 0 | 31 | |
| A011106 | Breast, Neoadj, ALTERNATE study | 15-FEB-14 | 281 | 120 | |
| A011401 | Breast, adj, Stage II/III HER2-, weight loss | 29-AUG-16 | 481 | 244 | |
| A011502 | Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo | 08-DEC-16 | 0 | 226 | |
| A221405 | Breast, ET interruption, Pregnancy Outcomes | 15-OCT-15 | 0 | 54 | |
| B51 | Breast, Regional Nodal XRT | 22-AUG-13 | 402 | 204 | |
| B55 | Brst, Adj Olaparib for BRCA,TNBC | 03-JUL-14 | 440 | 186 | |
| E1Z11 | Brst,Genetic Predictors of AIMSS | 10-MAY-13 | 75 | 23 | |
| E2112 | Brst,Adv,Exemestane+/-Entinostat | 02-JAN-14 | 316 | 175 | |
| EA1151 | Brst, Tomosynthesis Mammographic Screening | 06-JUL-17 | 0 | 76 | |
| NRGBR002 | Brst, OMBC, II-III, SoC +/- SBRT and/or SA | 24-DEC-14 | 0 | 136 | |
| NRGBR003 | Brst,Adj,TNBC,AC -> WP +/- Carbo | 22-JAN-15 | 342 | 173 | |
| NRGBR005 | Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | 13-APR-17 | 0 | 19 | |
| CCD | S1415CD | TrACER CSF Standing Order Intervention for FN | 01-SEP-16 | 6 | 12 |
| S1417CD | Colorectal, Cost Cohort Study | 13-MAY-16 | 102 | 23 | |
| S1703 | Met Breast, STM-monitoring v Usual Care | 16-JUL-18 | 0 | 53 | |
| A011104 | Preoperative Breast MRI | 21-FEB-14 | 121 | 41 | |
| A191402C | PROS, Testing Decision Aids for Minority Men | 14-JUL-17 | 0 | 10 | |
| EAQ162CD | CCD, Financial Burden, Colon & Rectal Cancer | 17-MAY-18 | 0 | 67 | |
| ERLYTX | S1609 | Rare Tumor, Comb Nivo/Ipi | 13-JAN-17 | 316 | 158 |
| A071102 | GBM, adj TMZ +/- Veliparib | 19-SEP-14 | 362 | 139 | |
| A071401 | Prog Meningiomas,SMO/AKT/NF2 Inhib | 06-AUG-15 | 308 | 120 | |
| ARST1321 | NonRhabdo STS,Pazopanib (PAZNTIS) | 16-MAY-14 | 259 | 119 | |
| EAY131 | MATCH | 12-AUG-15 | 382 | 207 | |
| GI | S1613 | mCRC, Adv/Met, TP vs CETIRI | 09-OCT-17 | 0 | 127 |
| S1815 | Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel | 03-DEC-18 | 0 | 4 | |
| A021501 | Adeno Panc,Borderline Resect,Chemo vs ChemoRT | 01-DEC-16 | 0 | 30 | |
| A021502 | Colon, Stg III, Chemo +/- Atezol, ATOMIC | 12-SEP-17 | 0 | 47 | |
| EA2142 | GI NEC, Adv G3, EP vs TMZ + CAP | 06-NOV-15 | 211 | 88 | |
| EA2161 | PANC, Adv Rapalog Resistant PNETs, MLN0128 | 01-FEB-17 | 0 | 8 | |
| EA2165 | Anal, Stg II-III, Nivolumab after CMT | 13-APR-18 | 0 | 16 | |
| N1048 | Rectal,LocalAdv,ChemoRT+/-FOLFOX | 13-JAN-12 | 0 | 155 | |
| NRGGI002 | Rectal, Ph II, Sensitization using TNT | 12-OCT-16 | 371 | 153 | |
| NRGGI004 | Colorectal, Stg IV, dMMR Immuno-Therapy | 07-NOV-17 | 0 | 41 | |
| GU | S1500 | pRCC,Adv, Sunitinib vs MET inhib | 05-APR-16 | 211 | 88 |
| S1602 | Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 07-FEB-17 | 174 | 69 | |
| S1605 | Blad, BCG-Unresponsive NMIBC, Atezolizumab | 07-FEB-17 | 190 | 88 | |
| S1802 | Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 17-SEP-18 | 0 | 50 | |
| A031102 | GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 01-JUL-15 | 56 | 34 | |
| A031501 | Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs | 21-SEP-17 | 0 | 115 | |
| EA8143 | RCC, HR, Surg +/- Nivolumab (PROSPER) | 02-FEB-17 | 0 | 143 | |
| EA8153 | Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) | 08-FEB-18 | 0 | 24 | |
| NRGGU002 | Pros, RT + ADT After RP +/- Adj Docetaxel | 30-DEC-16 | 0 | 118 | |
| R0924 | Pros, NADT+WPRT vs. NADT+P&SV RT | 07-JUL-11 | 0 | 128 | |
| LEUK | S1312 | ALL, CD22+, REL/REF, Inotuzumab+CVP | 01-APR-14 | 1 | 1 |
| S1712 | CML, chronic phase, TKI +/- Ruxolitinib | 20-JUL-18 | 0 | 50 | |
| E1910 | BCR-ABL-neg, B ALL, Blinatumomab | 23-DEC-13 | 167 | 81 | |
| E2906 | AML, Age 60+, Clo vs Dauno+Cy | 24-FEB-11 | 143 | 68 | |
| NHLBIMDS | LEUK, National MDS Study | 05-APR-16 | 210 | 80 | |
| LUNG | S1400 | SCCA,Adv, Biomarker Master | 15-JUN-14 | 448 | 205 |
| S1400F | Non-Match: MEDI4736 + Tremelimumab | 02-OCT-17 | 0 | 207 | |
| S1619 | Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC | 03-NOV-17 | 0 | 26 | |
| S1701 | Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | 09-AUG-18 | 0 | 19 | |
| A081105 | ALCHEMIST1, EGFR mut, Erlotinib | 02-JAN-14 | 0 | 250 | |
| A151216 | ALCHEMIST0 - screening | 06-FEB-14 | 491 | 250 | |
| C30610 | SCLC, Thoracic RT | 21-MAR-08 | 167 | 91 | |
| E4512 | ALCHEMIST2, ALK mut, Crizotinib | 18-AUG-14 | 482 | 249 | |
| EA5142 | ALCHEMIST3, Non-match, Nivolumab | 16-MAY-16 | 461 | 245 | |
| EA5161 | Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo | 02-MAY-18 | 0 | 126 | |
| NRGCC003 | SCLC, PCI or HA-PCI | 07-DEC-15 | 260 | 126 | |
| LYMPH | S1608 | FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 10-AUG-17 | 0 | 103 |
| A051301 | ABC DLBCL, Auto HCT and Ibrutinib/Placebo | 15-JUL-16 | 164 | 67 | |
| EA4151 | Lymph, AHCT +/-Ritux, MRD Neg | 29-AUG-17 | 0 | 59 | |
| MELAN | S1320 | Adv, BRAF mut, Inter v Contin | 22-JUL-14 | 233 | 99 |
| S1512 | Melan, Adv, Desmoplastic, MK-3475 (pembro) | 20-OCT-16 | 87 | 41 | |
| S1607 | MELAN, Adv, T-VEC, MK-3475 | 02-OCT-17 | 0 | 18 | |
| S1616 | MELAN, Adv, Ipilimumab ± Nivolumab | 17-JUL-17 | 0 | 97 | |
| EA6134 | Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 15-DEC-15 | 361 | 143 | |
| EA6141 | Melan, Avd, Nivolumab+Ipi ± Sargmostim | 01-MAR-16 | 223 | 93 | |
| MMYEL | S1702 | AL Amyloidosis, Relapsed, Isatuximab | 08-MAR-18 | 0 | 63 |
| E1A11 | MM, frontline, BLD vs CLD | 22-NOV-13 | 298 | 127 | |
| OTHER | A091304 | Adv Sarc, MLN0128 v Pazopanib, PhI/II | 26-JAN-15 | 233 | 80 |
| A091305 | HN, Adv, Thyroid PPAR agonist + Chemo | 01-SEP-14 | 85 | 26 | |
| A091401 | Sarc, | 18-JUN-15 | 182 | 72 | |
| A091404 | HN, AR+, Enzalutamide | 25-SEP-15 | 77 | 40 | |
| EA3132 | HN SCC, Stg III-IV , Adj RT +/- Cisp | 29-MAR-16 | 0 | 67 | |
| EAF151 | Brain, GBM, Bev, Blood Volume | 14-APR-17 | 0 | 33 | |
| EAQ152 | Communication & education in tumor profiling | 26-SEP-16 | 181 | 78 | |
| G0263 | Cerv, Stg I/IIA, adjv RT vs chemoRT | 12-APR-10 | 0 | 74 | |
| N0577 | BRN, Glio,Tem vs Tem+RT vsRT+PVC | 22-SEP-09 | 171 | 77 | |
| NRGBN001 | HN, novel vs. std chemoradiation + chemo | 28-AUG-15 | 0 | 97 | |
| NRGGY005 | OVAR, Cedir vs Olaparib vs C+O vs Std of Care | 06-FEB-16 | 332 | 142 | |
| NRGGY009 | Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev | 12-MAY-17 | 0 | 12 | |
| NRGHN001 | Nasopharyngeal , Indiviual Tx EBV | 21-APR-14 | 209 | 73 | |
| R0724 | Cervical, Chem+RT +/- Adj. Chemo | 15-JAN-14 | 205 | 83 | |
| R1216 | HN, Adv,Cis vs Dtx vs Dtx+Cetux | 18-MAR-13 | 201 | 85 | |
| PREV | S0820 | PACES: ColrecStg0-3 Blind DFMO/Sulindac | 01-MAR-13 | 146 | 60 |
| A211102 | Breast, Atypia via RPFNA, Metformin v Placebo | 01-FEB-15 | 12 | 5 | |
| SURV | S1316 | Compar. Effectiv. Trial for MBO | 01-AUG-14 | 3 | 5 |
| S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol | 15-SEP-17 | 0 | 98 | |
| E1Q11 | EROS: Reproductive Health in Cancer Survivors | 30-SEP-15 | 0 | 44 | |
| EA9131 | Leuk, Strategy to decrease early APL deaths | 16-AUG-17 | 0 | 25 | |
| SXQOL | A221101 | Glioma, Nuvigil/Placebo Fatigue | 03-JUN-13 | 72 | 28 |
| A221505 | Brst, Hypofractionated Post Mast Rad | 01-FEB-18 | 0 | 21 | |
| NRGGU003 | Pros, Post-Prostatectomy HYPORT vs COPORT | 28-JUL-17 | 0 | 116 | |